The antibody recognizes an epitope on the alpha-chain of Complement C3 (Western blot). The antibody inhibits the anaphylactic function of C3a: the capacity of C3a to induce serotonin release from thrombocytes in vitro is inhibited; similarly, treatment of C3a with the antibody inhibits the C3a-induced skin reaction in vivo. The antibody is, in combination with antibodies to the C3b fragment, an excellent control for distinguishing ubiquitous or nonspecifically bound native C3 from the biologically active C3 fragment. Nonactivated C3 still bears the C3a determinant, whereas activated C3 (C3b, C3d) is C3a-negative. It is therefore useful for immunopathological assays (demonstration of C3 deposition in biopsies) and for C3a assays.
Immunogen
Human complement component C3
Application
Research Category Inflammation & Immunology
Research Sub Category Immunoglobulins & Immunology
This Anti-Complement C3a Antibody, clone H13 is validated for use in ELISA, IH, WB for the detection of Complement C3a.
Physical form
Format: Purified
Protein A purified immunoglobulin lyophilized from PBS, pH 7.4, containing 0.5% BSA and 0.09% sodium azide. Reconstitute with 1 mL distilled water.
Storage and Stability
Maintain at 2°-8°C for up to 12 months from date of receipt.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Journal of clinical microbiology, 48(4), 1139-1149 (2010-01-15)
More than 10 million people are thought to be infected with Trypanosoma cruzi, primarily in the Americas. The clinical manifestations of Chagas' disease (CD) are variable, but most subjects remain asymptomatic for decades. Only 15 to 30% eventually develop terminal
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
